Research Reference
MOTS-c
Mitochondrial peptide — longevity and metabolic health
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide. Published research documents it activating AMPK and enhancing glucose metabolism, insulin sensitivity, and fatty acid oxidation (Lee et al., 2015). It is frequently described as an "exercise mimetic" — though it complements exercise rather than replacing it.
No MOTS-c formulation is FDA-approved. All protocols are derived from published research and community experience.
Standard community protocol: 1 mg daily (5 days on, 2 days off) for 8 weeks, then 8 weeks off. Morning dosing aligns with natural metabolic rhythms and complements exercise.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 0.5 mg | 10 units | 0.1 mL | Daily SubQ (5-on/2-off)Starter |
| 1 mg | 20 units | 0.2 mL | Daily SubQ (5-on/2-off)Standard |
| 5 mg | 100 units | 1 mL | Daily SubQAdvanced (community) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
For a 10 mg vial with 2 mL bacteriostatic water, the concentration is 5 mg/mL. A 1 mg dose draws to 20 units (0.2 mL) on a U-100 insulin syringe.
Gently swirl — do not shake. Refrigerate after mixing and use within 28 days. Store unreconstituted vials at -20°C.
Cycling Protocol
The standard cycle is 1 mg daily (5 on / 2 off) for 8 weeks, then 8 weeks off. The rationale is AMPK–mTOR balance — chronic AMPK activation can suppress mTOR-mediated protein synthesis, so cycling allows the body to alternate between metabolic optimization (AMPK-dominant) and growth/repair (mTOR-dominant) phases.
Morning dosing aligns with natural metabolic rhythms. Exercise itself induces endogenous MOTS-c expression, and intermittent dosing (3x/week) was sufficient to improve physical capacity in aged mice (Lai et al., 2021).
An enhanced community protocol for metabolic targeting uses 5 mg SC 3x/week (assessment) → 5 mg 5x/week (active, 6–8 weeks) → 5 mg 3x/week (maintenance). The 5 mg dose is derived from animal studies using 5 mg/kg IP, which does not translate linearly to humans.
Routes of Administration
Subcutaneous injection is the standard route — abdomen, thigh, or love handles, using a 29–31 gauge insulin syringe. Volume is typically 0.2 mL for the standard 1 mg dose.
Stacking Protocols
| Stack | Purpose | Protocol | | --- | --- | --- | | MOTS-c + SS-31 (Elamipretide) | Dual mitochondrial approach | MOTS-c 1 mg + SS-31 500 mcg, both 5-on/2-off | | MOTS-c + NAD+ | Metabolic + energy substrate | MOTS-c 1 mg 5-on/2-off + NAD+ 100 mg 2–3x/week |
MOTS-c and SS-31 work through completely different mechanisms — MOTS-c signals via AMPK while SS-31 physically stabilizes cardiolipin.
Side Effects & Safety
- Injection site reactions — redness, mild pain, or swelling (more common with larger volumes)
- Transient hypoglycemia-like symptoms — light-headedness or hunger if dosed fasted, reflecting glucose-lowering activity
- Mild GI discomfort — nausea or stomach upset, typically first few days only
- Mild flushing or warmth — occasional, transient
- AMPK–mTOR trade-off — chronic AMPK activation may suppress muscle protein synthesis (rationale for cycling)
- Drug interaction: metformin — both activate AMPK; additive glucose-lowering possible
No MOTS-c formulation is FDA-approved. Populations excluded from published trials include Type 1 diabetes subjects.
Research Basis
MOTS-c was first identified by Changhan Lee and colleagues in 2015 as a mitochondrial-encoded signaling peptide (Lee et al., 2015).
AMPK activation mechanism: MOTS-c targets the methionine-folate cycle, raising cellular AICAR concentrations that activate AMPK. Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus to regulate adaptive gene expression (Kim et al., 2018).
Late-life efficacy: MOTS-c treatment initiated at the mouse equivalent of ~70 human years improved physical capacity and healthspan with intermittent dosing (3x/week) (Lai et al., 2021).
Exercise mimetic context: MOTS-c activates overlapping pathways with exercise (AMPK, glucose uptake, fat oxidation) but does not replicate cardiovascular adaptation, bone loading, or neuromuscular development. It is best understood as a metabolic supplement to exercise, not a replacement.